お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
938713

ネオアンチゲン癌ワクチンの世界市場:2025年までの予測と市場機会

Global Neoantigen Cancer Vaccine Market By Product, By Neoantigen Type, By Route of Administration, By Cell, By Technology, By Delivery Mechanism, By Application, By Region, Competition, Forecast & Opportunities, 2025

出版日: | 発行: TechSci Research | ページ情報: 英文 111 Pages | 納期: お問合せ

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.83円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

ネオアンチゲン癌ワクチンの世界市場:2025年までの予測と市場機会
出版日: 2020年05月01日
発行: TechSci Research
ページ情報: 英文 111 Pages
納期: お問合せ
  • 全表示
  • 概要
  • 目次
概要

世界のネオアンチゲン癌ワクチン市場は、予測期間中に35%に近いCAGRで成長すると予測されています。市場の成長に関与する主要な要因は、技術の急速な革新とヘ医療セクターのインフラストラクチャーの開発です。

当レポートは、世界のネオアンチゲン癌ワクチン市場をセグメント別や地域別で調査したもので、市場規模および市場シェアの予測、促進要因と課題、市場動向、競合情勢、企業プロファイルなどの情報を提供しています。

目次

第1章 製品の概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界のネオアンチゲン癌ワクチン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 製品別(個別化、市販)
    • ネオ抗原の種類別(核酸、樹状細胞、腫瘍細胞、合成長ペプチド(SLP))
    • 投与経路別(静脈内、筋肉内、経皮、その他)
    • 細胞別(自己、同種)
    • 技術別(全ゲノムシーケンス、RNAシーケンス、HLAタイピング)
    • 送達機構別(遺伝子銃、エレクトロポレーション、リポソーム、ビロソームなど)
    • 用途別(黒色腫、脳がん、胃腸、肺など)
    • 会社別(2019)
    • 地域別
  • 市場魅力指数

第5章 アジア太平洋のネオアンチゲン癌ワクチン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 製品別
    • ネオ抗原タイプ別
    • 投与経路別
    • セル別
    • 技術別
    • 用途別
    • 国別
  • 市場魅力指数
  • アジア太平洋:国分析
    • 中国
    • インド
    • 日本
    • 韓国
    • シンガポール
    • オーストラリア

第6章 欧州のネオアンチゲン癌ワクチン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 製品別
    • ネオ抗原タイプ別
    • 投与経路別
    • セル別
    • 技術別
    • 用途別
    • 国別
  • 市場魅力指数
  • 欧州:国分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第7章 北米のネオアンチゲン癌ワクチン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 製品別
    • ネオ抗原タイプ別
    • 投与経路別
    • セル別
    • 技術別
    • 用途別
    • 国別
  • 市場魅力指数
  • 北米:国分析
    • 米国
    • メキシコ
    • カナダ

第8章 南米のネオアンチゲン癌ワクチン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 製品別
    • ネオ抗原タイプ別
    • 投与経路別
    • セル別
    • 技術別
    • 用途別
    • 国別
  • 市場魅力指数
  • 南米:国分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第9章 中東・アフリカのネオアンチゲン癌ワクチン市場の展望

  • 市場規模と予測
  • 市場シェアと予測
    • 製品別
    • ネオ抗原タイプ別
    • 投与経路別
    • セル別
    • 技術別
    • 用途別
    • 国別
  • 市場魅力指数
  • 中東・アフリカ:国分析
    • 南アフリカ
    • サウジアラビア
    • UAE

第10章 市場力学

  • 促進要因
  • 課題

第11章 市場動向と発展

第12章 競合情勢

  • 競合の展望
  • 主要企業のプロファイル
    • Avidea Technologies
    • Agenus
    • Roche
    • Nouscom
    • Merck
    • Pfizer
    • Advaxis
    • Medigene
    • Genocea Biosciences
    • Gritstone Oncology
    • Gilead Sciences
    • Eli Lilly
    • Novogene
    • Moderna
    • BioNTech
    • Ziopharm
    • ISA Pharmaceutical
    • Vaccibody
    • Brightpath Bio
    • Vaximm

第13章 戦略的推奨事項

第14章 免責事項

目次
Product Code: 4566

Global neoantigen cancer vaccine market is projected to grow at a CAGR of close to 35% during the forecast period. The key factor responsible for the growth of neoantigen cancer vaccine market is rapid innovations in technology as well as infrastructural developments in healthcare sector. Additionally, growing investments by the governing bodies and healthcare providers is another major factor that is anticipated to bode well for the growth of neoantigen cancer vaccine market across the globe in the coming years. Moreover, rising cases of cancers is further anticipated to bolster the market growth through 2025.

The global neoantigen cancer vaccine market is segmented based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, region and company. Based on route of administration, the market can be segmented into intravenous, intramuscular, transdermal and others. Out of which, the intravenous segment dominated the market until 2019 and is further anticipated to be the fastest-growing application segment of the neoantigen cancer vaccine market during the forecast period as well. This growth can be accredited to quick response as well as the to the fact that drug dosage can be controlled easily. Along with that, intramuscular injections can be used rather than intravenous because some drugs cause irritation to veins when injected intravenously. This is expected to result in high growth of intramuscular route of administration segment over the coming years.

Major players operating in the global neoantigen cancer vaccine market include Avidea Technologies, Agenus, Roche, Nouscom, Merck, Pfizer, Advaxis, Medigene, Genocea Biosciences, Gritstone Oncology, Gilead Sciences, Eli Lilly, Novogene, Moderna, BioNTech, Ziopharm, ISA Pharmaceutical, Vaccibody, Brightpath Bio, Vaximm, etc. The companies operating in the market across the globe are focussing more towards expanding their share in the market.

Years considered for this report:

Historical Years: 2015-2018

Base Year: 2019

Estimated Year: 2020

Forecast Period: 2021-2025

Objective of the Study:

  • To analyse and forecast the market size of global neoantigen cancer vaccine market.
  • To classify and forecast global neoantigen cancer vaccine market based on product, neoantigen type, route of administration, cell, technology, delivery mechanism, application, company and regional distribution.
  • To identify drivers and challenges for global neoantigen cancer vaccine market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global neoantigen cancer vaccine market.
  • To conduct pricing analysis for global neoantigen cancer vaccine market.
  • To identify and analyse the profile of leading players operating in global neoantigen cancer vaccine market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of manufacturers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the new products, distribution channels and presence of all major players across the globe.

TechSci Research calculated the market size of global neoantigen cancer vaccine market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Neoantigen cancer vaccine manufacturers, suppliers, distributors and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to neoantigen cancer vaccine
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as manufacturers, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global neoantigen cancer vaccine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Market, By Product:

Personalized neo-antigen vaccine

Off-the shell neoantigen vaccine

  • Market, By Neoantigen Type:

Nucleic acid

Dendritic cell

Tumor cell

Synthetic Long Peptide

  • Market, By Route of Administration:

Intravenous

Intramuscular

Transdermal

Others

  • Market, By Cell:

Autologous

Allogenic

  • Market, By Technology:

Whole Genome Sequencing

RNA Sequencing

HLA Typing

  • Market, By Delivery Mechanism:

Gene gun

Electroporation

Liposomes

Virosomes

Others

  • Market, By Application:

Melanoma

Brain cancer

Gastrointestinal

Lung

Others

  • Market, By Region:

North America

  • United States
  • Mexico
  • Canada

Europe

  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Singapore

Middle East and Africa

  • South Africa
  • Saudi Arabia
  • UAE

South America

  • Brazil
  • Argentina
  • Colombia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global neoantigen cancer vaccine market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

2. Research Methodology

3. Executive Summary

4. Global Neoantigen Cancer Vaccine Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value & Volume
  • 4.2. Market Share & Forecast
    • 4.2.1. By Product (Personalized neo-antigen vaccine, Off-the shell neoantigen vaccine)
    • 4.2.2. By Neoantigen Type (Nucleic acid, Dendritic cell, Tumor cell and Synthetic long peptide (SLP))
    • 4.2.3. By Route of Administration (Intravenous, Intramuscular, Transdermal, Others)
    • 4.2.4. By Cell (Autologous, Allogenic)
    • 4.2.5. By Technology (Whole Genome Sequencing, RNA Sequencing, HLA Typing)
    • 4.2.6. By Delivery Mechanism (Gene gun, Electroporation, Liposomes, Virosomes and Others)
    • 4.2.7. By Application (Melanoma, Brain cancer, Gastrointestinal, Lung and Others)
    • 4.2.8. By Company (2019)
    • 4.2.9. By Region
  • 4.3. Market Attractiveness Index

5. Asia-Pacific Neoantigen Cancer Vaccine Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value & Volume
  • 5.2. Market Share & Forecast
    • 5.2.1. By Product
    • 5.2.2. By Neoantigen Type
    • 5.2.3. By Route of Administration
    • 5.2.4. By Cell
    • 5.2.5. By Technology
    • 5.2.6. By Application
    • 5.2.7. By Country
  • 5.3. Market Attractiveness Index
  • 5.4. Asia-Pacific: Country Analysis
    • 5.4.1. China Neoantigen Cancer Vaccine Market Outlook
      • 5.4.1.1. Market Size & Forecast
        • 5.4.1.1.1. By Value
      • 5.4.1.2. Market Share & Forecast
        • 5.4.1.2.1. By Product
        • 5.4.1.2.2. By Neoantigen Type
        • 5.4.1.2.3. By Route of Administration
        • 5.4.1.2.4. By Cell
        • 5.4.1.2.5. By Technology
        • 5.4.1.2.6. By Application
    • 5.4.2. India Neoantigen Cancer Vaccine Market Outlook
      • 5.4.2.1. Market Size & Forecast
        • 5.4.2.1.1. By Value
      • 5.4.2.2. Market Share & Forecast
        • 5.4.2.2.1. By Product
        • 5.4.2.2.2. By Neoantigen Type
        • 5.4.2.2.3. By Route of Administration
        • 5.4.2.2.4. By Cell
        • 5.4.2.2.5. By Technology
        • 5.4.2.2.6. By Application
    • 5.4.3. Japan Neoantigen Cancer Vaccine Market Outlook
      • 5.4.3.1. Market Size & Forecast
        • 5.4.3.1.1. By Value
      • 5.4.3.2. Market Share & Forecast
        • 5.4.3.2.1. By Product
        • 5.4.3.2.2. By Neoantigen Type
        • 5.4.3.2.3. By Route of Administration
        • 5.4.3.2.4. By Cell
        • 5.4.3.2.5. By Technology
        • 5.4.3.2.6. By Application
    • 5.4.4. South Korea Neoantigen Cancer Vaccine Market Outlook
      • 5.4.4.1. Market Size & Forecast
        • 5.4.4.1.1. By Value
      • 5.4.4.2. Market Share & Forecast
        • 5.4.4.2.1. By Product
        • 5.4.4.2.2. By Neoantigen Type
        • 5.4.4.2.3. By Route of Administration
        • 5.4.4.2.4. By Cell
        • 5.4.4.2.5. By Technology
        • 5.4.4.2.6. By Application
    • 5.4.5. Singapore Neoantigen Cancer Vaccine Market Outlook
      • 5.4.5.1. Market Size & Forecast
        • 5.4.5.1.1. By Value
      • 5.4.5.2. Market Share & Forecast
        • 5.4.5.2.1. By Product
        • 5.4.5.2.2. By Neoantigen Type
        • 5.4.5.2.3. By Route of Administration
        • 5.4.5.2.4. By Cell
        • 5.4.5.2.5. By Technology
        • 5.4.5.2.6. By Application
    • 5.4.6. Australia Neoantigen Cancer Vaccine Market Outlook
      • 5.4.6.1. Market Size & Forecast
        • 5.4.6.1.1. By Value
      • 5.4.6.2. Market Share & Forecast
        • 5.4.6.2.1. By Product
        • 5.4.6.2.2. By Neoantigen Type
        • 5.4.6.2.3. By Route of Administration
        • 5.4.6.2.4. By Cell
        • 5.4.6.2.5. By Technology
        • 5.4.6.2.6. By Application

6. Europe Neoantigen Cancer Vaccine Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value & Volume
  • 6.2. Market Share & Forecast
    • 6.2.1. By Product
    • 6.2.2. By Neoantigen Type
    • 6.2.3. By Route of Administration
    • 6.2.4. By Cell
    • 6.2.5. By Technology
    • 6.2.6. By Application
    • 6.2.7. By Country
  • 6.3. Market Attractiveness Index
  • 6.4. Europe: Country Analysis
    • 6.4.1. France Neoantigen Cancer Vaccine Market Outlook
      • 6.4.1.1. Market Size & Forecast
        • 6.4.1.1.1. By Value
      • 6.4.1.2. Market Share & Forecast
        • 6.4.1.2.1. By Product
        • 6.4.1.2.2. By Neoantigen Type
        • 6.4.1.2.3. By Route of Administration
        • 6.4.1.2.4. By Cell
        • 6.4.1.2.5. By Technology
        • 6.4.1.2.6. By Application
    • 6.4.2. Germany Neoantigen Cancer Vaccine Market Outlook
      • 6.4.2.1. Market Size & Forecast
        • 6.4.2.1.1. By Value
      • 6.4.2.2. Market Share & Forecast
        • 6.4.2.2.1. By Product
        • 6.4.2.2.2. By Neoantigen Type
        • 6.4.2.2.3. By Route of Administration
        • 6.4.2.2.4. By Cell
        • 6.4.2.2.5. By Technology
        • 6.4.2.2.6. By Application
    • 6.4.3. United Kingdom Neoantigen Cancer Vaccine Market Outlook
      • 6.4.3.1. Market Size & Forecast
        • 6.4.3.1.1. By Value
      • 6.4.3.2. Market Share & Forecast
        • 6.4.3.2.1. By Product
        • 6.4.3.2.2. By Neoantigen Type
        • 6.4.3.2.3. By Route of Administration
        • 6.4.3.2.4. By Cell
        • 6.4.3.2.5. By Technology
        • 6.4.3.2.6. By Application
    • 6.4.4. Italy Neoantigen Cancer Vaccine Market Outlook
      • 6.4.4.1. Market Size & Forecast
        • 6.4.4.1.1. By Value
      • 6.4.4.2. Market Share & Forecast
        • 6.4.4.2.1. By Product
        • 6.4.4.2.2. By Neoantigen Type
        • 6.4.4.2.3. By Route of Administration
        • 6.4.4.2.4. By Cell
        • 6.4.4.2.5. By Technology
        • 6.4.4.2.6. By Application
    • 6.4.5. Spain Neoantigen Cancer Vaccine Market Outlook
      • 6.4.5.1. Market Size & Forecast
        • 6.4.5.1.1. By Value
      • 6.4.5.2. Market Share & Forecast
        • 6.4.5.2.1. By Product
        • 6.4.5.2.2. By Neoantigen Type
        • 6.4.5.2.3. By Route of Administration
        • 6.4.5.2.4. By Cell
        • 6.4.5.2.5. By Technology
        • 6.4.5.2.6. By Application

7. North America Neoantigen Cancer Vaccine Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value & Volume
  • 7.2. Market Share & Forecast
    • 7.2.1. By Product
    • 7.2.2. By Neoantigen Type
    • 7.2.3. By Route of Administration
    • 7.2.4. By Cell
    • 7.2.5. By Technology
    • 7.2.6. By Application
    • 7.2.7. By Country
  • 7.3. Market Attractiveness Index
  • 7.4. North America: Country Analysis
    • 7.4.1. United States Neoantigen Cancer Vaccine Market Outlook
      • 7.4.1.1. Market Size & Forecast
        • 7.4.1.1.1. By Value
      • 7.4.1.2. Market Share & Forecast
        • 7.4.1.2.1. By Product
        • 7.4.1.2.2. By Neoantigen Type
        • 7.4.1.2.3. By Route of Administration
        • 7.4.1.2.4. By Cell
        • 7.4.1.2.5. By Technology
        • 7.4.1.2.6. By Application
    • 7.4.2. Mexico Neoantigen Cancer Vaccine Market Outlook
      • 7.4.2.1. Market Size & Forecast
        • 7.4.2.1.1. By Value
      • 7.4.2.2. Market Share & Forecast
        • 7.4.2.2.1. By Product
        • 7.4.2.2.2. By Neoantigen Type
        • 7.4.2.2.3. By Route of Administration
        • 7.4.2.2.4. By Cell
        • 7.4.2.2.5. By Technology
        • 7.4.2.2.6. By Application
    • 7.4.3. Canada Neoantigen Cancer Vaccine Market Outlook
      • 7.4.3.1. Market Size & Forecast
        • 7.4.3.1.1. By Value
      • 7.4.3.2. Market Share & Forecast
        • 7.4.3.2.1. By Product
        • 7.4.3.2.2. By Neoantigen Type
        • 7.4.3.2.3. By Route of Administration
        • 7.4.3.2.4. By Cell
        • 7.4.3.2.5. By Technology
        • 7.4.3.2.6. By Application

8. South America Neoantigen Cancer Vaccine Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value & Volume
  • 8.2. Market Share & Forecast
    • 8.2.1. By Product
    • 8.2.2. By Neoantigen Type
    • 8.2.3. By Route of Administration
    • 8.2.4. By Cell
    • 8.2.5. By Technology
    • 8.2.6. By Application
    • 8.2.7. By Country
  • 8.3. Market Attractiveness Index
  • 8.4. South America: Country Analysis
    • 8.4.1. Brazil Neoantigen Cancer Vaccine Market Outlook
      • 8.4.1.1. Market Size & Forecast
        • 8.4.1.1.1. By Value
      • 8.4.1.2. Market Share & Forecast
        • 8.4.1.2.1. By Product
        • 8.4.1.2.2. By Neoantigen Type
        • 8.4.1.2.3. By Route of Administration
        • 8.4.1.2.4. By Cell
        • 8.4.1.2.5. By Technology
        • 8.4.1.2.6. By Application
    • 8.4.2. Argentina Neoantigen Cancer Vaccine Market Outlook
      • 8.4.2.1. Market Size & Forecast
        • 8.4.2.1.1. By Value
      • 8.4.2.2. Market Share & Forecast
        • 8.4.2.2.1. By Product
        • 8.4.2.2.2. By Neoantigen Type
        • 8.4.2.2.3. By Route of Administration
        • 8.4.2.2.4. By Cell
        • 8.4.2.2.5. By Technology
        • 8.4.2.2.6. By Application
    • 8.4.3. Colombia Neoantigen Cancer Vaccine Market Outlook
      • 8.4.3.1. Market Size & Forecast
        • 8.4.3.1.1. By Value
      • 8.4.3.2. Market Share & Forecast
        • 8.4.3.2.1. By Product
        • 8.4.3.2.2. By Neoantigen Type
        • 8.4.3.2.3. By Route of Administration
        • 8.4.3.2.4. By Cell
        • 8.4.3.2.5. By Technology
        • 8.4.3.2.6. By Application

9. Middle East and Africa Neoantigen Cancer Vaccine Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value & Volume
  • 9.2. Market Share & Forecast
    • 9.2.1. By Product
    • 9.2.2. By Neoantigen Type
    • 9.2.3. By Route of Administration
    • 9.2.4. By Cell
    • 9.2.5. By Technology
    • 9.2.6. By Application
    • 9.2.7. By Country
  • 9.3. Market Attractiveness Index
  • 9.4. MEA: Country Analysis
    • 9.4.1. South Africa Neoantigen Cancer Vaccine Market Outlook
      • 9.4.1.1. Market Size & Forecast
        • 9.4.1.1.1. By Value
      • 9.4.1.2. Market Share & Forecast
        • 9.4.1.2.1. By Product
        • 9.4.1.2.2. By Neoantigen Type
        • 9.4.1.2.3. By Route of Administration
        • 9.4.1.2.4. By Cell
        • 9.4.1.2.5. By Technology
        • 9.4.1.2.6. By Application
    • 9.4.2. Saudi Arabia Neoantigen Cancer Vaccine Market Outlook
      • 9.4.2.1. Market Size & Forecast
        • 9.4.2.1.1. By Value
      • 9.4.2.2. Market Share & Forecast
        • 9.4.2.2.1. By Product
        • 9.4.2.2.2. By Neoantigen Type
        • 9.4.2.2.3. By Route of Administration
        • 9.4.2.2.4. By Cell
        • 9.4.2.2.5. By Technology
        • 9.4.2.2.6. By Application
    • 9.4.3. UAE Neoantigen Cancer Vaccine Market Outlook
      • 9.4.3.1. Market Size & Forecast
        • 9.4.3.1.1. By Value
      • 9.4.3.2. Market Share & Forecast
        • 9.4.3.2.1. By Product
        • 9.4.3.2.2. By Neoantigen Type
        • 9.4.3.2.3. By Route of Administration
        • 9.4.3.2.4. By Cell
        • 9.4.3.2.5. By Technology
        • 9.4.3.2.6. By Application

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

12. Competitive Landscape

  • 12.1. Competition Outlook
  • 12.2. Players Profiled (Leading Companies)
    • 12.2.1. Avidea Technologies
    • 12.2.2. Agenus
    • 12.2.3. Roche
    • 12.2.4. Nouscom
    • 12.2.5. Merck
    • 12.2.6. Pfizer
    • 12.2.7. Advaxis
    • 12.2.8. Medigene
    • 12.2.9. Genocea Biosciences
    • 12.2.10. Gritstone Oncology
    • 12.2.11. Gilead Sciences
    • 12.2.12. Eli Lilly
    • 12.2.13. Novogene
    • 12.2.14. Moderna
    • 12.2.15. BioNTech
    • 12.2.16. Ziopharm
    • 12.2.17. ISA Pharmaceutical
    • 12.2.18. Vaccibody
    • 12.2.19. Brightpath Bio
    • 12.2.20. Vaximm

13. Strategic Recommendations

14. About Us & Disclaimer

株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.